HSP70 IN THE DEVELOPMENT OF EXPERIMENTAL TOXIC HEPATITIS
Abstract
The relevance of drug-induced liver injury (DILI) lies in the fact that it remains one of the most challenging problems in clinical hepatology. It develops against the background of the widespread use of potentially hepatotoxic medications, polypharmacy, self-medication, and the concomitant intake of herbal remedies and dietary supplements. Although the overall population incidence of DILI is relatively low, it is one of the leading causes of acute liver failure and may be associated with high mortality, particularly in cases of delayed withdrawal of the causative agent and severe injury phenotypes.
Keywords
drug-induced liver injury; HSP70; hepatotoxicity; cellular stress response.
References
- Allison R.D., Fontana R.J. Drug induced liver injury: clinical perspectives and future directions // Hepatology Communications. — 2023. — Vol. 7, No. 2. — P. e1023–e1035. — DOI: 10.1002/hep4.2101
- Björnsson E.S. Epidemiology and risk factors for drug-induced liver injury // Clinical Liver Disease. — 2022. — Vol. 19, No. 1. — P. 9–15. — DOI: 10.1002/cld.1187
- Fontana R.J., Seeff L.B. Drug-induced liver injury: pathogenesis, diagnosis and management // Gastroenterology. — 2023. — Vol. 164, No. 4. — P. 1056–1072. — DOI: 10.1053/j.gastro.2022.12.045
- Hosack T., Lumley M., Björnsson E. Drug-induced liver injury: a comprehensive review of current practice // World Journal of Gastroenterology. — 2023. — Vol. 29, No. 12. — P. 1821–1844. — DOI: 10.3748/wjg.v29.i12.1821
- Teschke R., Danan G. Drug-induced liver injury: importance of causality assessment using RUCAM // Journal of Clinical and Translational Hepatology. — 2021. — Vol. 9, No. 3. — P. 393–403. — DOI: 10.14218/JCTH.2020.00109